Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-nCoV-IH/IM vs Inactivated Vaccine in Children and Adolescents
NCT05330871Phase 2Unknown
- Sponsor
- Seventh Medical Center of the People's Liberation Army General Hospital
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Seventh Medical Center of the People's Liberation Army General Hospital. Primary endpoints: Immunogenicity of anti SARS-CoV-2 neutralizing antibody and Incidence of adverse reaction (AR). Status: unknown.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05330871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330871.